DRUG · Mapped RxNorm record
Ipilimumab
Normalized identity: ipilimumabView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
NCT03333616
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Nivolumab
Normalized identity: nivolumabView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedNivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Genitourinary Cancerunresolved
Non-urothelial Bladderunresolved
Non-urothelial Upper Tractunresolved
Penile Cancerverified · MONDO: penile cancer
Non-adenocarcinoma Prostate Cancerunresolved
Refractory Germ-cellunresolved
Interventions
IpilimumabDRUG · verified · RxNorm: ipilimumab
NivolumabDRUG · verified · RxNorm: nivolumab
Sponsors & collaborators
Dana-Farber Cancer Institutelead sponsor
Bristol-Myers Squibbcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03333616 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.